
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings Inc has demonstrated resilience in a dynamic market, with expectations for improved valuation driven by solid operational results, even amidst structural changes in reimbursement. The company's strategic positioning within the regenerative medicine sector, coupled with an upward adjustment in reimbursement rates for CY2026, enhances its potential for future operating profit growth. As the market consolidates, Organogenesis is poised to capture additional market share, contributing to a positive long-term outlook for its stock performance.
Bears say
The financial outlook for Organogenesis Holdings Inc. appears negative due to anticipated challenges in revenue growth, particularly with PuraPly products and pricing pressures from Medicare Part B on amniotic products. The company is also facing significant competitive pressures, which could hinder its market share, along with regulatory challenges and the potential for lower uptake of new products. Additionally, the projection of high research and development costs without corresponding growth improvements presents further downside risks to financial performance.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares